Ignacio Faus
Fortune : 12 890 $ au 30/09/2026
Fortune : 12 890 $ au 30/09/2026
Dr. Ignacio Faus is a Deputy Chief Executive Officer & Director at NFL Biosciences SAS and an Advisor at DRI Healthcare.
He is on the Board of Directors at NFL Biosciences SAS. Dr. Faus was previously employed as a Chief Executive Officer by Mologen AG, a Chief Executive Officer by Palau Pharma SA, a Manager-Business Development by J.
Uriach y Cia SA, a Chief Executive Officer & Director by Genmedica Therapeutics SL, and an Executive Director by Sage Healthcare Ltd. He received his MBA from Kellogg School of Management and a doctorate degree from Indiana University.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
DRI Healthcare Trust
DRI Healthcare Trust Investment Trusts/Mutual FundsMiscellaneous Operates as a royalty trust 0 % | 13/11/2025 | 1 000 ( 0 % ) | 12 890 $ | 30/09/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| NFL BIOSCIENCES | Directeur/Membre du Conseil | 17/10/2024 |
DRI Healthcare
DRI Healthcare Investment ManagersFinance DRI Healthcare invests in royalty interests in leading pharmaceutical and biotechnology companies, research institutions, universities and inventors. | Consultant / Advisor | - |
| Sociétés | Poste | Fin |
|---|---|---|
| MOLOGEN AG | Directeur Général | 31/03/2019 |
Palau Pharma SA
Palau Pharma SA BiotechnologyHealth Technology Provides research and development services to the pharmaceutical sector | Directeur Général | 01/01/2013 |
Noucor Health SA
Noucor Health SA Miscellaneous Commercial ServicesCommercial Services Engages in research, development and manufacturing of medicines & food supplements | Corporate Officer/Principal | 01/11/2006 |
Sage Healthcare Ltd.
Sage Healthcare Ltd. Miscellaneous Commercial ServicesCommercial Services Provides management consulting services to the healthcare industry | Directeur/Membre du Conseil | - |
Genmedica Therapeutics SL
Genmedica Therapeutics SL BiotechnologyHealth Technology Engages in the research and development of treatments for metabolic disorders | Directeur Général | - |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 9 |
|---|---|
DRI Healthcare
DRI Healthcare Investment ManagersFinance DRI Healthcare invests in royalty interests in leading pharmaceutical and biotechnology companies, research institutions, universities and inventors. | Finance |
MOLOGEN AG
MOLOGEN AG Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops immunotherapies for the treatment of infectious diseases | Health Technology |
Indiana University
Indiana University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Noucor Health SA
Noucor Health SA Miscellaneous Commercial ServicesCommercial Services Engages in research, development and manufacturing of medicines & food supplements | Commercial Services |
Genmedica Therapeutics SL
Genmedica Therapeutics SL BiotechnologyHealth Technology Engages in the research and development of treatments for metabolic disorders | Health Technology |
Palau Pharma SA
Palau Pharma SA BiotechnologyHealth Technology Provides research and development services to the pharmaceutical sector | Health Technology |
Sage Healthcare Ltd.
Sage Healthcare Ltd. Miscellaneous Commercial ServicesCommercial Services Provides management consulting services to the healthcare industry | Commercial Services |
Kellogg School of Management
Kellogg School of Management Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
NFL Biosciences SAS
NFL Biosciences SAS BiotechnologyHealth Technology Operates as a biotechnology company that develops botanical treatments for addictions | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national